Researchers led by Ludwig Lausanne’s Denarda Dangaj Laniti and Fernanda Herrera reported the findings of a phase 1 clinical trial (RACIN) examining whether low-dose radiotherapy (LDRT) can turn “cold” (immune-excluded) tumors “hot” in preparation for checkpoint blockade immunotherapy. They showed that LDRT can reprogram immune-excluded metastases and bolster a CD8+ T cell responses (stained red, above) before immunotherapy is even started
Read MoreThe Ludwig Institute for Cancer Research and Keystone Symposia announced a joint meeting, titled Tumor and Host Metabolism: Integrating, Molecular Cellular and Systemic Interactions, to be hosted by Ludwig Princeton, March 7-10, 2027. This is the first of a series of symposia planned by the two organizations—and hosted at each of the Ludwig Institute Branches—on topics of critical importance to cancer research.
A quick Q&A with physician-researchers Bernhard Gentner and Caroline Arber, who join Ludwig Lausanne, and Christian Hinrichs, who joins Ludwig Princeton, as Clinical Scholars of the Ludwig Institute for Cancer Research.
a
Read More
